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1288Classic and Overlap Chronic Graft-versus-Host Disease
(cGVHD) Is Associated with Superior Outcome after
Extracorporeal Photopheresis (ECP)
Madan H. Jagasia,1 Bipin N. Savani,1,2 George Stricklin,3 Brian Engelhardt,1 Adetola Kassim,1
Sheri Dixon,1 Heidi Chen,4 Wichai Chinratanalab,1,2 Stacey Goodman,1,2 John P. Greer,1
Friedrich Schuening1The National Institutes of Health (NIH) classification of graft-versus-host disease (GVHD) is a significant
improvement over prior classifications, and has prognostic implications. We hypothesized that the NIH clas-
sification of GVHD would predict the survival of patients with GVHD treated with extracorporeal photo-
pheresis (ECP). Sixty-four patients with steroid refractory/dependent GVHD treated with ECP were
studied. The 3-year overall survival (OS) was 36% (95% confidence interval [CI] 13-59). Progressive
GVHD was seen in 39% of patients with any acute GVHD (aGVHD) (classic acute, recurrent acute, overlap)
compared to 3% of patients with classic chronic GVHD (cGVHD) (P5.002). OS was superior for patients
with classic cGVHD (median survival, not reached) compared to overlap GVHD (median survival, 395 days,
95% CI 101 to not reached) and aGVHD (delayed, recurrent or persistent) (median survival, 72 days, 95% CI
39-152). In univariate analyses, significant predictors of survival after ECP included GVHD subtype, bilirubin,
platelet count, and steroid dose. In multivariate analyses overlap plus classic cGVHD was an independent
prognostic feature predictive of superior survival (hazard ratio [HR] 0.34, 95% CI 0.14-0.8, p5 .014). This
study suggests that NIH classification can predict outcome after ECP for steroid refractory/dependent
GVHD.
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resisINTRODUCTION
Graft-versus-host disease (GVHD), a common
complication occurring after allogeneic stem cell
transplant (SCT), has been historically classified as
acute (aGVHD) (onset within first 100 days of alloge-
neic SCT) and chronic (cGVHD) (onset after 100 days
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6/j.bbmt.2009.06.007festations that resemble a variety of autoimmune disor-
ders [3,4], and has been previously classified as limited
and extensive, although the prognostic significance of
this classification is unclear [5]. The National Insti-
tutes of Health (NIH) published consensus criteria
for diagnosis and classification of cGVHD, and relies
on the phenotype of GVHD rather than timing of
GVHD. GVHD is classified as classic aGVHD (onset
before 100 days), recurrent aGVHD, delayed aGVHD
(onset after day 100), persistent aGVHD, overlap
GVHD (features of both aGVHD and cGVHD),
and classic cGVHD [6].
A variety of agents has been studied for steroid
dependent/refractory GVHD [7-15]. Extracorporeal
photopheresis (ECP) is effective in the treatment of
GVHD, and has been used with variable efficacy
[16-20]. The target organ responsiveness varies widely,
and depends on type of GVHD (acute or chronic), and
previous treatment (steroid-refractory or dependent).
A recent randomized study showed that ECP decreases
the steroid usage in a subset of patients with GVHD
[21]. None of the previous studies of ECP for
GVHD treatment have incorporated the NIH
Table 1. Baseline Characteristics
Number Percentage
Age (median, range, years) 45 (23-67)
Sex (recipient, male/female) 39/25 61/39
Disease
Acute myelogenous leukemia 15 23
Acute lymphoblastic leukemia 6 9
Chronic myelogenous leukemia 10 16
Chronic lymphocytic leukemia 4 6
Multiple myeloma 7 11
Myelodysplastic syndrome 8 13
Lymphoma 8 13
Other 8 9
Disease risk
Low 24 38
Intermediate 6 9
High 29 45
Stem cell source
Bone marrow 18 28
Peripheral blood
stem cells
44 69
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rolled in ‘‘cGVHD’’ ECP studies, have recurrent
aGVHD or overlap GVHD. We and others have
shown the prognostic value of this classification in
retrospective series, and have demonstrated that
patients with classic and overlap cGVHD have the
best survival compared to other phenotypes [22,23].
As most transplant centers are using the NIH classifi-
cation for GVHD, it is important to validate the prog-
nostic ability of the NIH classification to predict the
outcome of GVHD treated with ECP to allow better
patient selection for ECP and allow rational develop-
ment of clinical trials pertaining to the use of ECP.
This is the first report showing that the outcome of
patients with GVHD treated with ECP is influenced
by the clinical phenotype as proposed by the NIH
classification.Other 2 3
Donor
Related 34 53
Unrelated 30 47
Regimen
Ablative 42 66
Reduced intensity/nonmyeloablative 22 34
CMV
Recipient (+/ 2) 38/21 60/33
Donor (+/ 2) 27/32 42/50
CMV indicates cytomegalovirus.
Some percentages do not add up to 100 because of missing data.
Ablative regimens: cyclophosphamide 120 mg/kg and total body irradia-
tion (TBI) 1200 cGy; cyclophosphamide 120 mg/kg, and busulfan 16 mg/
kg; cyclophosphamide 7200 mg/m2, etoposide 2000 mg/m2, BCNU
400 mg/m2.
Reduced-intensity regimens: fludarabine 90 mg/m2 and busulfan 8 mg/kg
with TBI 400 cGy; fludarabine 90 mg/m2, and busulfan 8 mg/kg, fludara-
bine 90 mg/m2 and busulfan 8 mg/kg with antithymocyte globulin, fludar-
abine 90 mg/m2, and melphalan 140 mg/m2 with antithymocyte globulin.
Nonmyeloablative: fludarabine 90 mg/m2 and TBI 200 cGy.PATIENTS AND METHODS
Sixty-four consecutive patients who started ECP
(1997-2008) for treatment ofGVHDafter an allogeneic
SCTwere included in the study cohort. All patients un-
derwent SCTon standard of care or institutional review
board (IRB) approved protocols. All patients signed
IRB-approved data consents. ECP specific parameters,
including frequency, number of treatment sessions, and
duration were abstracted frommedical charts. Detailed
reviews of GVHD characteristics were done, and
GVHDwas reclassified in accordance with the classifi-
cation as proposed by theNIHconsensus criteria and as
described previously [22]. Details regarding immuno-
suppressive therapy (IST) and steroid usage were ob-
tained, including dose at start of ECP and at month 2,
and at subsequent 2 monthly intervals until the end of
ECP. A decrease in the steroid dose while on ECP
was considered as a surrogate marker of a patient deriv-
ing clinical benefit from ECP and was analyzed.
Transplant Regimens
Table 1 summarizes the SCT characteristics. Stan-
dard GVHD prophylaxis regimens with cyclosporine
(CsA)/tacrolimus and methotrexate (MTX) (myeloa-
blative (MA) transplants) or mycophenolate moefetil
(MMF) (reduced intensity conditioning [RIC] and
nonmyeloablative [NMA] transplants) were used. All
patients received standard institutional care regarding
antimicrobial prophylaxis, cytomegalovirus (CMV)
monitoring, and treatment.
GVHD Treatment
For treatment of aGVHD the following general
principles were used: grade II or higher aGVHD was
treated with 1-2 mg/kg of methylprednisolone or an
equivalent dose of prednisone for 7 to 14 days, followed
by a taper of 10% every 5 to 7 days. Treatment ofsteroid refractory aGVHD was variable, and included
use of ECP, and other agents like antithymocyte glob-
ulin (ATG), and infliximab.
Treatment of cGVHD was variable, but followed
some general principles. Patients with isolated mouth,
ocular, or minimal skin cGVHDwere treated with top-
ical steroids. Patients with significant cGVHD were
treated with calcineurin inhibitor along with systemic
steroids (prednisone). Although duration and dosing
of steroids were not standardized, patients typically re-
ceived treatment until all symptoms of cGVHD were
resolved or stabilized, and subsequent tapers of IST
were attempted. Patients were started on second-line
agents at the discretion of the treating physician.
Treatment with ECP
Patients were started on ECP if they were steroid de-
pendent (recurrence of GVHD with attempts at steroid
taper), steroid intolerant (eg, severe myopathy), steroid
refractory, or had concomitant infections that would pre-
clude a primary steroid based therapy (eg, multiple reac-
tivationsofCMV).Patientswere treatedonaweeklybasis
1290 Biol Blood Marrow Transplant 15:1288-1295, 2009M. H. Jagasia et al.with 2 pheresis sessions a week. This was continued for 3
to 4weeks and thendecreased to an every 2- to 3-week in-
terval.Thegoalwas togetpatients to anevery4-week fre-
quency.
Responses were assessed retrospectively by a single
investigator (B.S.). Responses were classified as com-
plete response (CR) if all clinical characteristics of
GVHD had normalized. Partial response (PR) was
defined as improvement, but not a complete resolution
of clinical and laboratory characteristics. Progressive
disease (PD) was defined as worsening of clinical char-
acteristics or new organ involvement. Stable disease
(SD) was defined as not meeting criteria for PR or
PD. Steroid and other IST dose reductions were not
used to assess response. All patients in the study cohort
were assigned a response status, unless documentation
to assess a response was missing (N5 2). Responses
were assessed at 2 months after initiating ECP. If
a patient had progressive GVHD, ECP was discontin-
ued. In patients who had clinical benefit (CR, PR, or
SD) from ECP, systemic steroids were gradually
tapered before attempting to stop ECP.
Statistical Analysis
Descriptive statistics, including median and ranges
for continuous variables, as well as percentages and
frequencies for categoric variables, were calculated.
Groups with nominal outcome were compared using
chi-square test or Fisher exact test; groups with contin-
uous outcomes were compared using Mann-Whitney
U-test. Spearman correlation was used to assess the
correlation between 2 continuous or ordinal variables.
Wilcoxon signed-rank test was used to compare paired
continuous variables. Overall survival (OS) (day of
SCT to the day of death or last follow-up) and ECP-
specific survival (the day of onset of ECP to the day of
death or last follow-up) was calculated. Kaplan-Meier
survival curves were calculated for each cohort (or
clinical group), and were compared using the log-rank
test. Because of the small sample size, in some analyses,
patients with any acute feature (aGVHD and overlap
GVHD) were combined and compared with classic
cGVHD. Cox regression models were constructed for
multivariate analyses for time to event endpoints. Cu-
mulative incidence of nonrelapse mortality (NRM)
was estimated using the Kaplan-Meier method with
adjusting for relapse as a competing risk event. All
reported P-values were 2 tailed and considered signifi-
cant at P\ .05. Analyses were performed using SPSS
version 13, SAS system version 9.1 and R version 2.1.1.RESULTS
Patient characteristics are shown in Table 1. The
median follow-up of the surviving patients from
initiation of ECP was 725 days (range: 192 to notreached). The 3-year OS of the entire cohort was
36% (95% CI 13-59).
GVHD Subtype and IST
GVHD at onset of ECP was classified per NIH
classification as: classic aGVHD (N5 15, 23%), re-
current aGVHD (N5 5, 8%), persistent aGVHD
(N5 0), overlap GVHD (N5 12, 19%), and classic
cGVHD (N5 31, 50%). One patient had inadequate
records for accurate assessment of GVHD subtype.
Of the 20 patients with various subtypes of aGVHD,
the maximum grades of aGVHD by Glucksberg crite-
ria at onset of ECP were as follows: 18 patients (90%)
had grade II-IV and 10 patients (50%) had grade III-
IV. Among patients with cGVHD (n5 43), the sub-
scale scores were captured. The mean sum of subscale
scores was 5.74 (range: 2-14). The subscale scores were
not significantly different in overlap compared to clas-
sic cGVHD (P5 .73). The scores for the various sub-
scales are as outlined in Table 2. cGVHD was
stratified as mild (N5 4, 9%), moderate (N5 23,
52%), and severe (N5 16, 36%) at ECP onset, and
was similar in patients with overlap (17%, 33%, and
50%) and classic chronic (7%, 61%, and 29%)
GVHD (P5 .51). The median number of recurrences
of GVHD prior to initiation of ECP was 2 (range: 0-6
recurrences), and was similar across all subtypes. Pa-
tients with any features of aGVHDhad amedian plate-
let count of 48.5 109/L compared to patients with
classic cGVHD (203 109/L, P\ .001). The median
bilirubin level was significantly different at time of
ECP initiation among the various GVHD subtypes
(any acute: 1.35 mg/dL versus classic chronic:
0.6 mg/dL, P5 .002).
The median steroid doses were 1.35 mg/kg,
0.7 mg/kg and 0.2 mg/kg in patients with aGVHD (re-
current, delayed, or persistent), overlap, and classic
cGVHD. Patients with manifestations of aGVHD
had a significantly higher steroid dose than classic
cGVHD (P\ .001).
ECP and Outcome
Patients were started on ECP at a median of 228
days post-SCT (range: 39-2943 days). Fifteen patients
(23%) started ECP prior to day 100, at a median of
50 days (range: 39-97 days). Patients with classic
cGVHD started ECP significantly late compared
to other subtypes (median, 786 versus 108 days,
P \ .001). The median number of ECP treatments
was 12 (range: 1-83 treatments). Patients with classic
cGVHD received more ECP treatments than other
subtype (14 versus 9, P5 .02). ECP was initiated for
steroid refractory GVHD without any recurrences in
5 (8%) patients, and after 1, 2, or 3 recurrences of
GVHD in 20 (31%), 13 (20%), and 13 (20%). ECP
was used in 11 patients (17%) who had 4 or greater
Table 2. Chronic GVHD Subscale
Score (Number/Percentage)
Subscale 0 1 2 3
Karnofsky performance status 0 25 (58) 14 (33) 2 (5)
Skin 12 (28) 4 (9) 14 (33) 11 (26)
Gastrointestinal 31 (72) 6 (14) 6 (14) 0
Ocular 27 (63) 5 (12) 11 (25) 0
Mouth 24 (56) 17 (40) 2 (4) 0
Pulmonary 35 (81) 5 (12) 1 (2) 2 (5)
Joints/fascia 32 (75) 9 (21) 1 (2) 1 (2)
Liver 20 (46) 14 (33) 7 (16) 2 (5)
Genitourinary
(females only, N 5 20)
14 (70) 4 (20) 0 0
GVHD indicates graft-versus-host disease.
Some percentages do not add up to 100 because of missing data.
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were not available. The number of recurrences of
GVHD prior to ECP for patients with classic
aGVHD, recurrent aGVHD, overlap, and classic
cGVHD were 0 (20%), 1 (30%), 2 (30%), and
3 (20%), respectively. Figure 1 is a flow diagram indi-
cating the number of patients with responses at various
time points during the ECP and details regarding rea-
sons for stopping ECP. Of the 64 patients treated with
ECP, 21 patients did not start month 2 of therapy.
Four of these patients are alive (CR5 1, PR5 1,
SD5 1, missing5 1). Similarly, of the 43 patients
that started month 2 of therapy, 19 did not start month
4. Fourteen of 19 patients are alive (CR5 2, PR5 10,
SD5 2). The continuation of ECP was determined by
a variety of factors, including response, degree of
systemic immmunosuppression, logistics of being
able to continue ECP, and treating-physician decision.Figure 1. Flow diagram summarizing disposition of patients during the
period of study analyses. The dark gray boxes with solid lines show the
response of GVHD to ECP (CR, complete response; PR, partial re-
sponse; SD, stable disease; PD, progressive disease). The light gray boxes
with the dashed lines show the GVHD subtype (CA, classic acute; RA,
recurrent acute; OV, overlap chronic; CC, classic chronic).*Reflects 1
missing patient.Response to ECP
CR, PR, and SDwas attained in 7 (11%), 30 (47%),
and 12 (19%) patients, respectively, and 13 (20%) had
PD. One patient (3%) was not evaluable because of
missing records. Forty-three patients (67%) were on
ECP at 2 months after initiation of therapy with a re-
sponse rate of 74% (32 of 43). Response rate of patients
who started month 4, 6, and 12 of ECP were 79% (19
of 24), 80% (4 of 5), and 100% (2 of 2), respectively.
Patients with\1 mg/kg steroid dose at onset of ECP
had a significantly higher incidence of response com-
pared to those with $1 mg/kg (90% versus 56%,
P5 .003).
Table 3 describes the details of responses as strat-
ified by GVHD type at ECP onset. PD was seen in
39%of patients with any aGVHD (classic acute, recur-
rent acute, overlap) compared to 3% of patients with
classic cGVHD (P5 .002). When GVHD was classi-
fied as chronic (classic plus overlap) versus acute (clas-
sic, recurrent), progression of GVHDwas significantly
lower in patients with cGVHD (14% versus 42%,
P5 .010).ECP use led to significant decrease in steroid doses
in patients with chronic (classic plus overlap) GVHD
(mean dose pre-ECP, 0.52 mg/kg versus 0.37 mg/kg
post-ECP, p5 .009).Subscale Score and Response
Subscale scores for all domains were assigned to
patients with overlap and chronic classic GVHD
(N5 43). Severity scores at ECP onset did not predict
response. Only KPS (0-1 versus 2-3) and GI subscale
scores (0-1 versus 2-3) were associated with GVHD
progression (4% versus 25%, P5 .067; 8% versus
50%, P5 .027). Subscale scores were lower (better)
Table 3. Responses to ECP Stratified by GVHD Subtype
Response (Number/Percentage)
GVHD Type CR PR SD PD
Classic acute (N5 15) 2 (13) 4 (27) — 8 (53)
Recurrent acute (N5 5) — 3 (60) 2 (40) —
Overlap (N5 12) 2 (17) 6 (50) — 4 (33)
Classic chronic (N5 31) 3 (10) 17 (55) 10 (32) 1 (3)
GVHD indicates graft-versus-host disease; ECP, extracorporeal photo-
pheresis; CR, complete response; PR, partial response; SD, stable dis-
ease; PD, progressive disease.
One patient was not evaluable because of missing records in the classic
acute group.
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(P5 .035) and joints/fascia (P5 .057). Although se-
verity did not change significantly with ECP, the over-
all score was significantly lower in responders
compared to nonresponders (P5 .0056).Survival after ECP
Thirty-four patients are surviving at the time of
analyses (30 patients deceased; nonrelapse, 24; relapse,
6), with an actuarial 3 year OS of 36% (95%CI 13-59).
OS was superior for patients with classic cGVHD (me-
dian survival, not reached) compared to overlap
GVHD (median survival, 395 days, 95% CI 101 to
not reached) and aGVHD (delayed, recurrent or per-
sistent) (median survival, 72 days, 95% CI 39-152) (P
\ .0001) (Figure 2A). Patients with aGVHD (classic
acute, recurrent acute) had a significantly decreased
OS compared to cGVHD (classic plus overlap) (P\
.001) (Figure 2B). This difference in OS (from ECP
onset) was more apparent when patients with any
aGVHD features (recurrent acute, delayed acute, and
overlap chronic) were compared with classic cGVHD
(3-year OS\25% versus 52%, P\ .0001) (Figure 2C).
The numbers of GVHD recurrences prior to initiation
of ECP were not significant in predicting OS (0-1 vs.
$2, P5 .39; 0-2 vs. $3, P5 .19). Response to ECP
was predictive of OS. The OS of responders (CR or
PR) (median survival, not reached), stabilization of
GVHD (median survival, 213 days, 95% CI 0-1058)
or progression (median survival, 36 days, 95% CI 14-
58) was significantly different (P\ .0001) (Figure 3).
Steroid dose at initiation of ECP was an important
predictor of OS (#1 mg/kg vs..1 mg/kg, not reached
versus 108 days, P5 .008).Figure 2. OS (from initiation of ECP) stratified by GVHD type. (A) Pa-
tients with aGVHD (persistent acute, recurrent acute, delayed acute)
overlap cGVHD, and classic cGVHD had significantly different OS
(P5.001). (B) aGVHD versus overlap plus classic cGVHD. (C) Any
aGVHD (classic, recurrent, overlap) versus classic cGVHD.Other Risk Factors Predicting Survival
The KPS subscale at onset of ECP was predictive
of OS (score 0-1 versus 2-3, median, not reached
versus 152 days, 95% CI 0-491, P5 .026). Similarly,
lower subscale scores (0-1) compared to a higher sub-
scale score ($2) were associated with improved OS for
liver (median, not reached versus 409 days, 95%CI 43-
750, P5 .027), GI tract (median, not reached versus
Figure 3. OS (from initiation of ECP) stratified by best response to
ECP. The overall survival of patients with response (CR or PR) (median
survival, not reached), stabilization of GVHD (median survival, 217 days)
or progression (median survival, 39 days) was significantly different
(P\.0001). CR, complete response; PR, partial response.
Figure 4. NRM with death from relapse as a competing risk. (A) NRM
of patients with aGVHD (classic acute, recurrent acute) compared with
cGVHD (overlap plus classic chronic) (P\.0001). (B) NRM of patients
with any aGVHD (classic acute, recurrent, overlap) compared with
classic cGVHD (P5.007).
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reached versus 39 days, 95% CI 0-134, P5 .033).
However, higher skin subscale scores (2-3 versus 0-1)
was associated with superior OS (median, not reached
versus 431 days, 95% CI 0-862, P5 .05). This proba-
bly reflects the higher percentage of patients with
cGVHD who had skin involvement.
Platelet count of#100 109/Lor.100 109/L at
the timeof initiationofECPwas an importantpredictor
of OS (68 days versus not reached, P\ .001). Bilirubin
level of#3 mg/dL or.3 mg/dL at the time of onset of
ECP was associated with significant difference in OS
(431 versus 32 days, P\ .001). Stem cell source, donor
status, absolute lymphocyte count at day 30, CD31 and
CD341 cells per kg (of recipient body weight) in the
infused graft, and age of #40 years or .40 years or as
a continuous variable had no impact on OS.
NRM
The 2-year cumulative NRM with relapse as
a competing risk for the entire cohort was 42% (95%
CI 27%-56%). NRM with relapse as a competing
risk was significantly higher in patients with aGVHD
(classic acute plus recurrent) compared to cGVHD
(overlap plus classic) (68% versus 29%, P \ .001)
(Figure 4A). Patients with classic cGVHDhad a signif-
icantly lower NRM compared to other types (57%
versus 28%, P5 .007) (Figure 4B).
Multivariable Analysis
Bilirubin level and platelet count were both predictors
of survival in univariate analyses, but were correlated with
each other (Spearman correlation520.696, P\ .001).
Steroid dose was correlated with GVHD type (Spearman
correlation520.611, P\ .001). Platelet count, donorstatus, andGVHDtypewere the3covariates thatwere an-
alyzed in the final multivariable model. GVHD type was
categorized as classic cGVHD versus other subtypes in
the first model and as classic cGVHD plus overlap versus
all other subtypes in the second model. Table 4 summa-
rizes the details of the multivariable model. GVHD type
was an independent predictor of survival in the second
model (hazard ratio [HR] 0.34, 95% CI 0.14-0.8,
P5 .0141). Platelet count was a predictor of survival in
both models.DISCUSSION
In this study, we show that the outcome of GVHD
when treated with ECP is influenced by the clinical
phenotype of GVHD as proposed by the NIH
Table 4. Multivariable Model
Variable Reference Hazard Ratio (95% CI) P-Value
Model 1
GVHD type* Acute plus
overlap
0.63 (0.22-1.79) .381
Donor status Related 0.52 (0.23-1.16) .108
Platelet count† (109/L) 39.25 0.1 (0.03-0.32) <.001
Model 2
GVHD type‡ Acute 0.34 (0.14-0.8) .014
Donor status Related 0.56 (0.26-1.22) .146
Platelet count† (109/L) 39.25 0.11 (0.04-0.33) <.001
GVHD indicates graft-versus-host diesase; CI, confidence interval.
*GVHD type: acute (classic acute, recurrent acute) plus overlap com-
pared to classic chronic.
†Platelet count: reference was 39.25 109/L. This was calculated as the
25th percentile from the range of platelet count and was compared with
the 75th percentile.
‡GVHD type: acute (classic acute, recurrent acute) compared to over-
lap plus classic chronic.
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ther advanced cases of GVHD. Patients with classic
cGVHD had the best survival compared to patients
with other subtypes of GVHD after ECP.
ECPhas been used to treatGVHDtypically for ste-
roid refractory, dependent or for ‘‘cGVHD’’ (GVHD
after day 100). In a pilot study of 21 patients, ECP
was used for treatment of steroid refractory aGVHD
[17]. In this cohort of patients, 60% achieved a CR after
3 months of ECP. A high proportion of patients with
skin only, liver only, or liver and skin involvement had
CRs. There were no responses to ECP seen with GI
GVHD or when all 3 target organs were involved.
This suggests that even in a seemingly homogenous co-
hort of steroid refractory aGVHD, response to ECP
varies with organ involvement. Patients who had a CR
with ECP had a significant better survival compared
to nonresponders. Results appear better when ECP is
initiated early in the course of steroid refractory
GVHD [16]. In this setting, GI GVHD responded to
ECP in 62% of the patients. In our cohort, 20 patients
had aGVHD (classic aGVHD5 15, recurrent
aGVHD5 5), and 10 patients had 2 or more GVHD
recurrences. Grade II and IV aGVHD was present in
50% of patients at time of ECP initiation with 70% of
patients with GI GVHD (20% with grade III-IV). In
this high-risk group of patients, ECP was initiated at
a median of 79 days after transplant and an OS of
20% (5/20) was seen.
The role of ECP may be more established in treat-
ing cGVHD (GVHD after day 100). In a pilot study of
15 patients, target organ sites that preferentially re-
sponded to ECP included skin, liver, and oral mucosa
[16]. These studies predated the development of the
NIH classification, and some patients with skin and
liver could represent patients with recurrent aGVHD,
delayed aGVHD, or overlap GVHD. We have previ-
ously shown that 36% and 37% of patients with limitedand extensive cGVHD are reclassified as recurrent
aGVHD, late aGVHD, or persistent aGVHD [22].
KPS is a known predictor of outcome in patients
with cGVHD. Previous studies have shown that
patients with aKPS of.90%have an excellent survival
(14/15 patients alive) [16]. In our study, KPS (score 0-1
versus 2-3) was predictive of response and survival.
Lower subscale scores for KPS, liver, lung, and gastro-
intestinal tract predicted a superior survival. Paradox-
ically, higher skin subscale scores (2-3 versus 0-1)
predicted a superior survival. The incidence of higher
skin subscale score was not significantly different in
patients with overlap compared to classic cGVHD. It
is known that ‘‘sclerotic’’ phenotype of cGVHD may
respond preferentially to ECP [20]. In the NIH classi-
fication, the higher skin scores (2-3) include not only
extent of rash $19% body surface area, but also in-
clude features of sclerosis. Thus, the higher skin scores
at ECP onset probably reflect the superior outcome of
patients with sclerotic GVHD with ECP. Retrospec-
tive assessment of overall clinical response of cGVHD
is not reliable, often because of lack of detailed
documentation and difficulty in estimating the resi-
dual damage from cGVHD versus ongoing activity.
Although, the NIH consensus guidelines have pro-
posed detailed response criteria, these are not applica-
ble for retrospective studies [24].
Steroid dose (\1 mg/kg or $1 mg/kg) at onset of
ECP was predictive of both response and survival.
Although, patients with cGVHD had a significantly
lower steroid dose than other subtypes at onset of
ECP, they continued to have a significant decrease in
steroid dose after ECP. It has been shown in a random-
ized study of ECP versus no ECP, that a.50% reduc-
tion in steroid dose along with a .25% reduction in
total skin score, was seen in 8% of patients compared
to no patients in the control arm (P5 .04) [21].
The precise biologic mechanism of action of ECP
remains elusive. This has hampered the development
of biomarkers to predict ECP responsiveness. Until
this is achieved, clinical factors and GVHD phenotype
to predict ECP responsiveness have to be relied upon.
This study identifies a subset of patients with cGVHD
(viz. classic cGVHD and overlap GVHD) that benefits
from ECP. Patients with steroid dependent/refractory
classic cGVHD have a significantly improved survival
with ECP compared to other GVHD subtypes. Future
trials should study early intervention with ECP in this
cohort of patients to try and decrease steroid and other
IST-related adverse effects. It is possible that modula-
tion of T-regulatory cells by ECP effect responses [25-
27]. IST agents that promote T-regulatory cell
survival may be potentially beneficial in combination
with ECP. A phase II/III trial studying such an
approach is being planned by Bone Marrow Trans-
plant Clinical Trial Network for new-onset cGVHD
with suboptimal response to steroids.
Biol Blood Marrow Transplant 15:1288-1295, 2009 1295ECP Outcome in GVHD and NIH ClassificationIn summary, our data shows that the recently pro-
posed NIH classification of GVHD helps in selecting
patients with steroid dependent/refractory GVHD
more likely tobenefit fromECPandpredicting response
to ECP. Patients with classic cGVHD and overlap
GVHD have a superior outcome when treated with
ECP. This is in contrast with the inability of ECP to
effectively salvage steroid dependent/refractory patients
with classic aGVHDor recurrent aGVHD.This subset
of patients should be considered for clinical trials inves-
tigating novel agents or in combination with ECP.AUTHORSHIP
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